17 Jun 2017 EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors
17 Jun 2017 Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017
17 Jun 2017 DARZALEX® (daratumumab) Approved by the U.S. FDA in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Who Have Received At Least Two Prior Therapies
17 Jun 2017 ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma
15 Jun 2017 Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed Hodgkin Lymphoma at the International Conference on Malignant Lymphoma
15 Jun 2017 LEO Pharma Starts Phase 3 Clinical Study for Tralokinumab in Atopic Dermatitis
15 Jun 2017 Generon Announces the Initiation of a Phase I Clinical Study for A-337, a CD3-Activating Bi-Specific Antibody Targeting EpCAM to Treat Solid Tumors
15 Jun 2017 Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
15 Jun 2017 Dose-escalation data show favorable safety profile and promising clinical activity for IPH4102
14 Jun 2017 Janssen Presents Long Term Phase 3 Efficacy and Safety Data of Sirukumab in Rheumatoid Arthritis Patients Who had an Inadequate Response and/or Who Were Intolerant to Anti-TNFs
14 Jun 2017 MabVax Therapeutics Reports Positive Phase 1 Results for MVT-2163 ImmunoPET Imaging Agent
14 Jun 2017 Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®
14 Jun 2017 Celltrion Healthcare showcases data supporting the efficacy and safety of Truxima® (CT-P10, biosimilar rituximab) in advanced follicular lymphoma and rheumatoid arthritis
14 Jun 2017 Alpine Immune Sciences Announces Presentation of Preclinical Data Showing Potency of Its First-Generation Dual ICOS and CD28 Antagonist vIgDs in an Animal Model
14 Jun 2017 Phase 1 Clinical Study Results of REMD Biotherapeutics’ Lead Product Candidate, REMD-477, Demonstrate Reduced Need for Insulin and Improved Blood Glucose Levels for Patients with Type 1 Diabetes
13 Jun 2017 New Study Shows Patients Treated With CroFab® Have Improved Recovery From Copperhead Envenomation
13 Jun 2017 FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of IgA Nephropathy
13 Jun 2017 Merck Provides Update on Multiple Myeloma Studies KEYNOTE-183 and 185 of KEYTRUDA® (pembrolizumab) in Combination with Other Therapies
13 Jun 2017 Acceleron Announces Top-Line Results from DART Phase 2 Study of Dalantercept in Advanced Renal Cell Carcinoma
12 Jun 2017 Drug Candidates Developed Using Zymeworks’ Azymetric Platform Nominated for Late-Stage, Preclinical Development by Lilly
12 Jun 2017 Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
12 Jun 2017 Alligator advances 4-1BB immuno-oncology antibody ATOR-1017 topre-clinical development
11 Jun 2017 Lilly's Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS
09 Jun 2017 Burtomab Receives Breakthrough Therapy Designation for advanced form of pediatric cancer
07 Jun 2017 Teva's Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase III Study in Episodic Migraine Prevention

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing